SCHEMBL1029586

SCHEMBL1029586

COC(=O)N1C/C(=C\c2ccc(F)cc2)c2c(c(C(=O)NC(C)c3ccccc3)nn2-c2ccc(Cl)cc2)C1

nearest known ligand 0.76

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 20/20 0.76
CNR2 P34972 11/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1029588 1.00 CNR1 (0.76) CNR1CNR2
SCHEMBL1029589 1.00 CNR1 (0.76) CNR1CNR2
SCHEMBL1029170 0.93 CNR1 (0.72) CNR1CNR2
SCHEMBL1029169 0.93 CNR1 (0.72) CNR1CNR2
SCHEMBL1029171 0.93 CNR1 (0.72) CNR1CNR2
SCHEMBL1030083 0.92 CNR1 (0.78) CNR1CNR2
SCHEMBL1029031 0.90 CNR1 (0.79) CNR1CNR2
SCHEMBL1029029 0.90 CNR1 (0.79) CNR1CNR2
SCHEMBL1027894 0.90 CNR1 (0.77) CNR1CNR2
SCHEMBL1027893 0.90 CNR1 (0.77) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1804791-B1 TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-01-19 EP claimed
US-20060089378-A1 Tetrahydro-pyridinyl pyrazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-27 US claimed
EP-1804791-B1 TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-01-19 EP disclosed
US-20060089378-A1 Tetrahydro-pyridinyl pyrazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089378-A1 Tetrahydro-pyridinyl pyrazole cannabinoid modulators CNR2, CNR1, GPR18 CNR1 2/4885CNR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.